MYGN
The good news: the loss got less ugly
Myriad Genetics came into Thursday’s Q2 print with a very biotech-company thing to say: the loss was smaller, but don’t get too cozy. Last year’s quarter had a hefty goodwill impairment charge hanging over it like a giant wet blanket, so the comparison got easier this time around.
The not-so-good news: revenue still slid
The bigger headline for investors is that revenue dropped 11%. That’s the kind of number that makes you squint at the growth story and ask, “Okay, so where’s the rebound?” Myriad also lowered its full-year 2026 revenue outlook, which usually means management sees the road ahead getting a little bumpier, not smoother.
Why you should care
For a molecular diagnostics company, sales trends matter a lot more than accounting cosmetics. A narrower loss can be nice, but if top-line momentum is fading and guidance is coming down, the market tends to focus on the second part of that sentence, not the first.
Big picture
This looks less like a victory lap and more like a reminder that investors want proof the business can grow, not just look better on paper than last year’s messy quarter.